Revance Therapeutics, Inc. (Revance) is a specialty biopharmaceutical company which develops botulinum toxin products for use in aesthetic and therapeutic indications. Revance has developed a platform technology, TransMTS®, that enables local, targeted delivery of botulinum toxin and other potent macromolecules across skin without patches, needles or other invasive procedures.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 04/02/13 | $33,000,000 | Series E |
Bio*One Capital Delphi Ventures Essex Woodlands NovaQuest Pharma Opportunities Fund Pac-Link Ventures Palo Alto Fund Shepherd Ventures Technology Partners Vivo Ventures | undisclosed |
